Live Breaking News & Updates on சமீபத்தியது உலகளாவிய புற்றுநோய்

Stay updated with breaking news from சமீபத்தியது உலகளாவிய புற்றுநோய். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Redirecting to Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC

May 24, 2021 healthcare
Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over a year of follow up and will be presented at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting on June 4.
“Patients with EGFR Exon20 insertion+ mNSCLC have no proven targeted therapy options,” said Suresh S. Ramalingam, MD, Deputy Director of Winship Cancer Institute of Emory University. “T ....

United States , Christopher Arendt , Sureshs Ramalingam , American Society Of Clinical Oncology , Takeda Pharmaceutical Company Limited , World Health Organization , Winship Cancer Institute Of Emory University , Takeda Pharmaceutical Company , Exchange Commission , American Cancer Society , Access Program , American Society , Clinical Oncology , Annual Meeting , Deputy Director , Winship Cancer Institute , International Association , Lung Cancer , Oncology Therapeutic Area Unit , Breakthrough Therapy Designation , New Drug Application , Expanded Access Program , Takeda Oncology , Orphan Drug Designation , Breakthrough Therapy , Drug Evaluation ,

Takeda Pharmaceutical Company Limited: Takeda präsentiert positive Ergebnisse für Mobocertinib bei Patienten mit EGFR-Exon-20-insertionspositivem mNSCLC, die bereits eine platinbasierte Chemotherapie erhalten haben

Takeda Pharmaceutical Company Limited: Takeda präsentiert positive Ergebnisse für Mobocertinib bei Patienten mit EGFR-Exon-20-insertionspositivem mNSCLC, die bereits eine platinbasierte Chemotherapie erhalten haben
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Egfr Exon , Kazumi Kobayashi , Lauren Padovan , Christopher Arendt , Scientific Research , World Health , Takeda Refer Company , Efforts Of Takeda In Research , Takeda Refer Company Limited , Research For People , China From The Drug Review Center , Dana Farber Cancer Institute , Oncology Our Core Mission In Research , Address Was , Irc The , Available Takeda Refer , Had Received , Parameters Results , Irc Confirmed Orr , May Have , Nineteen Patients , Medical Benefits , Oncology Therapeutic Area , Licensing Authorities Around , Details Please ,

Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy

Press release content from Business Wire. The AP news staff was not involved in its creation.
Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy
January 28, 2021 GMT
CAMBRIDGE, Mass. & OSAKA, Japan (BUSINESS WIRE) Jan 28, 2021
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced new data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in previously treated patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic non-small cell lung cancer (mNSCLC) will be presented as a late-breaking oral session at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) on Friday, January 29 SGT. ....

United States , Dana Farber Cancer Institute , United Kingdom , Kazumi Kobayashi , Christopher Arendt , Lauren Padovan , Better Health , Takeda Pharmaceutical Company Limited , Drug Review Center , World Health Organization , Drug Administration , Takeda Pharmaceutical Company , Exchange Commission , American Cancer Society , Pharmaceutical Company Limited , International Association , Lung Cancer , Dana Farber Cancer , Platinum Pretreated Population , Oncology Therapeutic Area Unit , Orphan Drug Designation , Breakthrough Therapy Designation , Breakthrough Therapy , World Health , Brighter Future , Rare Diseases ,